You are here

Imagin Medical Inc.

Imagin Medical Inc.
Listing Exchange: 
CSE
Status: 
Suspended
Industry: 
Technology
Symbol: 
IME
CSE Index: 
Currency: 

Imagin Medical is Building a Best-in-Class Urologic Oncology Company Developing technologies to better visualize and treat urologic cancers, including bladder and prostate cancer, through minimally invasive surgery

The Company believes its first product, the i/Blue Imaging System™, with its advanced proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting bladder cancer, helping to improve the surgical management of this disease.

Imagin’s follow-on product, the enCAGE Coil™ is a device with 510(k) clearance for soft tissue ablation. Imagin intends to refine the disposable bipolar radio frequency-based probe for use in the treatment of prostate cancer and benign prostate hypoplasia (BPH) and submit appropriate FDA premarket applications for the new indications.

After receipt of FDA clearance, Imagin believes the enCAGE Coil system for Prostate Cancer will address the limitations of current forms of treatment by enabling the surgeon to preset precise margins to target only the cancer cells, avoiding damage to the remaining prostate gland and surrounding erectile nerves that can impair urinary and sexual function.

Imagin’s proprietary technologies are poised to expand patient access and improve outcomes and quality of life.

You are here

Imagin Medical Inc. (IME)

SEDAR Information

Company Info

Address
890 West Pender St., Suite 600
Vancouver, BC V6C 1J9
Canada
Phone
833-246-2446
Email
[email protected]
Website
http://www.imaginmedical.com
Listing date
Wednesday, February 24, 2016
Transfer Agent
Computershare Investor Services Inc.
Investor Relations
John Vacha
Email
[email protected]
Auditor
De Visser Gray

Capitalization

Issued & Outstanding: 
10830116
Reserved for Issuance: 
26519687

Company Officers

E. James Hutchens, President & CEO
John Vacha, Chief Financial Officer (CFO)

Bulletins

05/02/2024

2024-0205 - Suspensions - TRYP, ALCU, IME, SCYB

Le 5 février/February 2024

Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading Rules. Cease Trade Orders have been issued by one or more securities commissions.